Glucotrack
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 6
- Market Cap
- -
- Introduction
GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.
Glucotrack Secures Ethical Approval for Long-Term Clinical Study of Implantable Blood Glucose Monitor
• Glucotrack has received ethical approval from St. Vincent's Hospital Melbourne HREC for a year-long clinical study of its implantable continuous blood glucose monitor in patients with type 1 and type 2 diabetes.
• The multi-center study will enroll up to 30 participants requiring intensive insulin therapy, with first implantations expected by July 2025 and potential extension to three years of monitoring.
• Unlike traditional CGMs that measure glucose in interstitial fluid, Glucotrack's device directly measures blood glucose with no wearable component and is designed to function for up to three years.
Glucotrack Advances to Clinical Stage with Innovative Implantable Continuous Blood Glucose Monitor
• Glucotrack has successfully transitioned from preclinical to clinical stage in 2024, completing its first human clinical study of a fully implantable continuous blood glucose monitoring (CBGM) system with promising results.
• The company's innovative CBGM technology features a 3-year sensor longevity, no on-body wearable component, and real-time measuring capabilities, potentially offering significant advantages for diabetes management.
• With $16.3 million secured through multiple funding rounds and FDA Investigational Device Exemption approval expected in Q4 2025, Glucotrack is positioned to advance clinical trials and development milestones throughout 2025.
Glucotrack Completes First Human Trial of Novel Implantable Blood Glucose Monitor
• Glucotrack successfully completed its first-in-human clinical study of a continuous blood glucose monitor implanted in the subclavian vein, with no serious adverse events reported.
• The innovative device is designed for direct blood glucose measurement and offers potential three-year longevity without requiring external components, marking a significant advance in diabetes monitoring.
• The four-day hospital study involving six diabetes patients demonstrated successful sensor placement and removal procedures, validating the safety profile of the implantable monitoring system.
© Copyright 2025. All Rights Reserved by MedPath